- Conditions
- Cervical Dystonia Adults ,, Abnormal Head Position and Neck Pain for These 7 Muscle Groups: Splenius,Scalene,Sterno-cleido-mastoid,Levator Scapulae,Semispinalis,Trapezius,and Longissimus.
- Interventions
- Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, Efficacy of Botox intramuscularly at Week 30, Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, Efficacy of Botox subdermally at Week 30, Adverse Reactions of Botox intramuscularly, Adverse Reactions of Botox subdermally
- Drug
- Lead sponsor
- li nguyen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Westminster, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 6,915
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Male Pattern Hair Loss
- Interventions
- HST 001, Phosphate Buffered Saline
- Biological · Other
- Lead sponsor
- Histogen
- Industry
- Eligibility
- 25 Years to 55 Years · Male only
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Encinitas, California
- Conditions
- Diabetic Peripheral Neuropathy
- Interventions
- Spinal Cord Stimulator Implantation (SCS)
- Device
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- Allopurinol, Keppra, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Allogeneic hematopoietic stem cell transplant, Filgrastim, antithymocyte globulin
- Drug · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 44 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Healthy Female Volunteers
- Interventions
- Neurotech Vital Device, Modified Neurotech Vital Device
- Device
- Lead sponsor
- Bio-Medical Research, Ltd.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Dahlonega, Georgia
- Conditions
- Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- G-CSF, Decitabine, Venetoclax
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Infertility
- Interventions
- AS900672-Enriched 50 microgram (mcg), AS900672-Enriched 100 mcg, AS900672-Enriched 150 mcg, Follitropin alfa 150 international unit (IU), Recombinant human chorionic gonadotropin (r-hCG)
- Drug
- Lead sponsor
- Merck KGaA, Darmstadt, Germany
- Industry
- Eligibility
- 18 Years to 36 Years · Female only
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Chronic Pain, Low Back Pain, Radiculopathy, Complex Regional Pain Syndrome (CRPS)
- Interventions
- High frequency stimulation, Low frequency stimulation
- Other
- Lead sponsor
- The Center for Clinical Research, Winston-Salem, NC
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Migraine
- Interventions
- levetiracetam, Transcranial Magnetic Stimulation
- Drug · Procedure
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Sleep Onset Latency
- Interventions
- Amber Tinted Glasses, Clear Glasses, Smart Lightbulbs
- Device
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 60 Months to 83 Months
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Alzheimer's Disease
- Interventions
- Repetitive Transcranial Magnetic Stimulation (rTMS), NICE Cognitive Training
- Device · Behavioral
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Crohn Disease
- Interventions
- Mesna, Cyclophosphamide, Filgrastim, Apheresis catheter placement, Leukapheresis, Fludarabine, Methylprednisolone, Diphenhydramine, Acetaminophen, anti-thymocyte globulin (rabbit), lymphocyte immune globulin, Peripheral Blood Stem Cell Infusion, Cytoxan
- Drug · Procedure · Biological
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 13 Years to 28 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Posttraumatic Stress Disorder
- Interventions
- Active Intermittent theta burst stimulation, Sham Intermittent theta burst stimulation
- Device
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Albuquerque, New Mexico
- Conditions
- Autism Spectrum Disorder
- Interventions
- Transcranial Magnetic Stimulation (TMS)
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Infertility
- Interventions
- INVOcell device, Traditional IVF
- Device · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 37 Years · Female only
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Active repetitive TMS, Sham repetitive TMS
- Device
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Peripheral Neuropathy
- Interventions
- Diode Laser fiber type Selective Stimulator, ZTlido 1.8 % Topical System, PeriCam PSI NR, Medoc Quantitative Sensory Testing, Inactive Topical System
- Procedure · Drug · Diagnostic Test + 1 more
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Salt Lake City, Utah
- Conditions
- Edema Leg
- Interventions
- geko Neuromuscular Electro Stimulator (NMES)
- Device
- Lead sponsor
- Firstkind Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Annapolis, Maryland • New Hartford, New York • New Albany, Ohio
- Conditions
- Anemia of Chronic Disease
- Interventions
- ESS (medical food/drug)
- Drug
- Lead sponsor
- Targeted Medical Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Lymphoma
- Interventions
- Filgrastim, Pegfilgrastim, Rituximab, Cyclophosphamide, Pegylated liposomal doxorubicin hydrochloride, Prednisone, Vincristine Sulfate
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 61 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 7
- States / cities
- Fort Smith, Arkansas • Grand Rapids, Michigan • Kalamazoo, Michigan + 4 more
- Conditions
- High Grade Glioma, CNS Tumor
- Interventions
- Entrectinib, Cyclophosphamide, Etoposide, Carboplatin, G-CSF, Pegfilgrastim, Surgery
- Drug · Biological · Procedure
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 3 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Pemphigus
- Interventions
- cyclophosphamide, filgrastim
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Early Stage Breast Cancer
- Interventions
- Paclitaxel, Neulasta
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Milford, Massachusetts • Weymouth, Massachusetts + 1 more
- Conditions
- Allergy
- Interventions
- Placebo, Xolair
- Drug
- Lead sponsor
- Creighton University
- Other
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska